REGENXBIO Inc. (RGNX)
| Market Cap | 328.28M -8.3% |
| Revenue (ttm) | 87.82M -44.0% |
| Net Income | -290.01M |
| EPS | -5.60 |
| Shares Out | 51.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,569,528 |
| Open | 6.73 |
| Previous Close | 6.35 |
| Day's Range | 6.31 - 6.88 |
| 52-Week Range | 5.46 - 16.19 |
| Beta | 1.12 |
| Analysts | Buy |
| Price Target | 24.18 (+280.79%) |
| Earnings Date | May 14, 2026 |
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-12... [Read more]
Financial Performance
In 2025, REGENXBIO's revenue was $170.44 million, an increase of 104.54% compared to the previous year's $83.33 million. Losses were -$193.88 million, -14.63% less than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for RGNX stock is "Buy." The 12-month stock price target is $24.18, which is an increase of 280.79% from the latest price.
News
REGENXBIO Transcript: RBC Capital Markets Global Healthcare Conference 2026
Plans are underway for a rolling BLA filing for Duchenne gene therapy, with strong efficacy and safety data supporting accelerated approval. Wet AMD pivotal trials are well-powered and on track, while the Hunter program is advancing post-clinical hold. Patient advocacy and product differentiation remain central.
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., May 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: 2026 RBC Capital Markets Global Healthcare Confere...
Regenxbio price target lowered to $16 from $17 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Regenxbio (RGNX) to $16 from $17 and keeps an Overweight rating on the shares.
Regenxbio price target lowered to $14 from $25 at BofA
BofA lowered the firm’s price target on Regenxbio (RGNX) to $14 from $25 and keeps a Buy rating on the shares. The firm views the RGX-202 AFFINITY DUCHENNE topline update…
Regenxbio price target lowered to $12 from $37 at Barclays
Barclays analyst Eliana Merle lowered the firm’s price target on Regenxbio (RGNX) to $12 from $37 and keeps an Overweight rating on the shares. The firm thinks further updates on…
REGENXBIO Earnings release: Q1 2026
REGENXBIO released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
REGENXBIO Quarterly report: Q1 2026
REGENXBIO has published its Q1 2026 quarterly earnings report on May 14, 2026.
Regenxbio reports Q1 EPS ($1.72) vs. 12c last year
Reports Q1 revenue $6.4M vs. $89M last year. “REGENXBIO (RGNX) enters a transformative year with positive momentum, reaching significant late-stage milestones to support our potential first- and best-...
Regenxbio expects cash, equivalents to fund operations into early 2027
Regenxbio (RGNX) expects its balance in cash, cash equivalents and marketable securities of $150.5M as of March 31 to fund its operations into early 2027. This cash runway guidance is…
Regenxbio’s RGX-202 shows efficacy in Phase 3 Duchenne trial
Regenxbio (RGNX) announced positive topline and interim functional data from the pivotal Phase III portion of the Phase I/II/III AFFINITY DUCHENNE trial of RGX-202, a potential best-in-class gene ther...
REGENXBIO Transcript: Study result
Pivotal phase III data for RGX-202 in Duchenne Muscular Dystrophy showed high microdystrophin expression, strong correlation with functional improvement, and a favorable safety profile. Investigators and families observed meaningful benefits, supporting plans for accelerated approval in 2027.
REGENXBIO Press release: Study result
REGENXBIO issued a press release on May 14, 2026, disclosing material business information to investors.
REGENXBIO Slides: Study result
REGENXBIO has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
Company announced positive topline results from pivotal Phase III AFFINITY DUCHENNE ® study of RGX-202 Primary endpoint achieved with high statistical significance Statistically significant correlatio...
Regenxbio's muscle disorder therapy meets main goal in late-stage study
Regenxbio said on Thursday that its experimental therapy to treat a muscle-wasting disorder met the main goal in a late-stage study.
REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
Achieved primary endpoint with high statistical significance; 93% of patients achieved microdystrophin expression above 10% (p
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
ROCKVILLE, Md., May 7, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting ("ASGCT 2026") taking place M...
REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy
-- Company will also report first quarter 2026 financial results and operational highlights -- ROCKVILLE, Md., May 6, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will ho...
REGENXBIO Proxy statement: Proxy filing
REGENXBIO filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
REGENXBIO Proxy statement: Proxy filing
REGENXBIO filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
REGENXBIO Proxy statement: Proxy filing
REGENXBIO filed a proxy statement on April 3, 2026, providing details for shareholder voting and corporate governance matters.
SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD
Notice to Pension Funds, Asset Managers, and Fiduciaries NEW YORK, March 26, 2026 /PRNewswire/ -- Institutional investors holding positions in REGENXBIO, Inc. (NASDAQ: RGNX) during the period between ...
Shareholders Sue RGNX Over Gene Therapy Study Claims
A class action lawsuit was filed against REGENEXBIO ($RGNX) on February 13, 2026. The federal securities class action alleges that plaintiffs acquired REGENEXBIO stock at artificially inflated prices ...
Regenxbio's Duchenne gene therapy shows improved muscle function in trial
Regenxbio said on Wednesday that an interim data from a early-to-mid stage study of its experimental gene therapy in patients with Duchenne muscular dystrophy showed continued improvement ...
Regenxbio reports interim data from Phase I/II AFFINITY DUCHENNE trial
REGENXBIO (RGNX) announced newinterim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, a potential gene therapy for Duchenne muscular dystrophy. Trial investigator Carolina Tesi-Rocha, M.D...